Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BTN162b2 mRNA COVID-19 vaccine during risankizumab treatment

J Dermatol. 2023 Feb;50(2):e79-e80. doi: 10.1111/1346-8138.16505. Epub 2022 Jul 7.

Authors

Kanako Tsunoda¹, Daisuke Watabe¹, Hiroo Amano¹

Affiliation

¹ Department of Dermatology, Iwate Medical University School of Medicine, Iwate, Japan.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Psoriasis* / drug therapy
Vaccination

Substances

BNT162 Vaccine
COVID-19 Vaccines
risankizumab